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Abstract. Background: Prevention of the development of
castration-resistant from hormone-naïve prostate cancer is
an important issue in maintaining the quality of life of the
patients. We explored the effect of 2’-hydroxyflavanone on
proliferation and androgen responsiveness using prostate
cancer cell lines. Materials and Methods: To investigate the
effect of 2’-hydroxyflavanone on proliferation, prostate
cancer cells were treated with 2’-hydroxyflavanone.
Androgen-responsiveness in LNCaP cells was confirmed by
luciferase assay after transfection of luciferase reporter
driven by prostate specific antigen promoter. To detect
androgen receptor (AR) expression, reverse transcriptase
polymerase chain reaction and western blot analysis were
conducted. Results: 2’-Hydroxyflavanone inhibited the
proliferation of PC-3 and DU145 cells by induction of
apoptosis. 2’-Hydroxyflavanone inhibited the proliferation of
LNCaP cells stimulated by androgens and attenuated
androgen-responsiveness through down-regulation of AR
protein. Conclusion: 2’-Hydroxyflavanone not only inhibited
proliferation of prostate cancer cells, but also repressed
androgen-responsiveness, suggesting that it might be an
useful agent in preventing recurrence of prostate cancer.
Since the androgen receptor (AR) axis is the main route for
development and progression of prostate cancer (PCa),
androgen-deprivation therapy (ADT) is conducted as a first-
line hormonal therapy using medical castration, such as
luteinizing hormone releasing hormone (LH-RH) agonists,
LH-RH antagonist, and antiandrogen for advanced PCa.
After an initial response to ADT, however, PCa eventually
loses responsiveness to ADT and progresses into what is
termed castration-resistant PCa (CRPC). 
The AR axis also plays an important part in the process
when hormone- sensitive PCa become CRPC. Although
serum testosterone decreases to less than 5% before starting
ADT, PCa adapts to low serum testosterone level by several
mechanisms. One other important factor is the adrenal
androgen, dehydroepiandrostenedione (DHEA). DHEA is
metabolized into testosterone, and then converted to
dihydrotestosterone (DHT) by 5α-reductase in PCa tissue,
which then activates the AR. In fact, the concentration of
DHT in PCa tissue remains 20 to 40% of pretreatment values
(1-3). Interaction of epithelial and stromal cells plays an
important role in the production of DHT in PCa tissue. After
castration, adrenal androgen DHEA is metabolized into DHT
in stromal cells and epithelial cells coordinately (4).
Moreover, CYP17A inhibitors, abiraterone acetate and TAK-
700, which inhibit conversion from pregnenolone into
DHEA, is effective for more than 70% of CRPC after
docetaxel-treatment. These results indicate that the AR axis
affects the recurrence of PCs even in patients resistant to
docetaxel.
Important enzyme in intratumoral androgen synthesis
mediating through interaction of epithelial and stromal cells
are type 3 and type 5 17β-hydroxysteroid dehydrogenase
(HSD17B3 and HSD17B5) and 3β-hydroxysteroid
dehydrogenase (3β-HSD). In particular, HSD17B3 catalyzes
the formation of testosterone from 4-androstenedione (adione)
in the testis and peripheral tissues (5). However, the function
of the testes is lost in PCa after ADT, the main androgen
synthesis enzyme in CRPC is HSD17B5. It is known that
AKR1C3 aldo-keto reductase acts as a HSD17B5 (6, 7).
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AKR1C3 was found to be up-regulated in patients with PCa,
especially, in those with metastatic PCa and CRPC (8-11).
Moreover, overexpression of AKR1C3 promoted PCa
proliferation (12). These findings suggest that hyperactivation
of AKR1C3 might affect the recurrence of PCa.
Flavonoids are a large group of polyphenolic compounds
present in foods and beverages of plant origin, and are
subdivided into six subclasses: flavonols, flavones,
flavanones, flavan-3-ols, anthocyanidins, and isoflavones (13).
Flavonoids display a broad range of pharmacological activity,
such as antioxidative, anti-inflammatory, and antiproliferative
activities (13-15). Flavonoids have been shown to inhibit
AKR1C3 activity in vitro (16, 17). 2’-Hydroxyflavanone
(2’HF), which is a flavanones in particular had a strong
inhibitory effect on AKR1C3 in vitro (16).
In the present study, we investigated the effect of 2’HF on
proliferation and androgen responsiveness using PCa cell
lines.      
Materials and Methods
Cell lines and cell proliferation assay. LNCaP and DU145 cells
(ATCC, Manassas, VA, USA) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 1%
penicillin/streptomycin (P/S; Invitrogen, Carlsbad, CA, USA) and
5% fetal bovine serum (FBS; Sigma–Aldrich, St. Louis, MO, USA),
respectively. PC-3 cells (ATCC) were cultured in RPMI -1640
supplemented with 1% P/S (Invitrogen) and 5% FBS. Twenty-four
hours after plating at a density of 5×104 cells onto 12-well plates
with DMEM-5% charcoal-stripped fetal calf serum (CCS; Thermo
Scientific HyClone, UK), cells were treated with ethanol, adione,
testosterone, DHT and/or 2’HF in DMEM-5% CCS and the media
were changed every two days. In each experiment, cells were
harvested and the numbers of the cells were counted in triplicate
using a hemocytometer. The data shown represent the means±SD of
three replicates.
Reverse transcriptase polymerase chain reaction (RT-PCR) and
western blot analysis. For RT-PCR, 24 hours after plating at a
density of 1×105 cells onto 6-well plates with DMEM-5% CCS,
cells were treated with or without Adione, DHT and/or 2’HF for 24
hours and total RNA was extracted. Total RNA extraction from cells
and RT-PCR for AR, prostate specific antigen (PSA), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
performed as described previously (2, 4). 
For western blot analysis, total protein was extracted from cells
as described previously (18). Protein was quantified according to
the method of Bradford, and equal amounts of protein were
electrophoresed on a 10% or 12.5% Ready Gel J (Bio-Rad,
Hercules, CA, USA). Membranes were incubated with mouse
monoclonal antibody against AR (NH27) (19) and GAPDH (Novus
Biologicals, Littleton, CO, USA). Horseradish peroxidase-
conjugated secondary antibody against mouse monoclonal or rabbit
monoclonal antibody was used and protein bands were visualized
and quantitated with chemiluminescent reagent (SuperSignal West
Pico Chemiluminescent Substrate; Pierce, Rockford, IL, USA) and
ChemiDoc XRS (Bio-Rad).
Recombinant plasmid constructs. Recombinant plasmid pEGFP-fAR
that expresses full-length wild-type AR fused with green fluorescent
protein (GFP) was constructed by inserting the full-length AR cDNA
of pSGAR2, which is driven by SV40 promoter (19) (at -24 to 3110
bp of start codon), into pEGFP-C1 (Invtrogen, CA, USA). The insert
configurations of fAR cDNAs were confirmed by sequence analysis. 
Luciferase assay. To evaluate AR transcriptional activity, 24 hours
after plating 5×104 cells on 12-well plates in DMEM-5% CCS,
LNCaP and PC-3 cells were transfected using Lipofectamine
transfection reaction (Invitrogen) using 0.5 μg of luciferase reporter
plasmid, pGL3PSAp-5.8, driven by a 5.8 kb PSA promoter (20).
Twenty-four hours after transfection, cells were treated by the
addition of DHT with and without 2’HF for 24 hours. After treated
cells were harvested, cells were lysed in luciferase lysis buffer
(Promega, Madison, WI, USA) and the luciferase activity was
quantitated by a luminometer. For overexpression of EGFP-fAR in
LNCaP cells, 5×104 LNCaP cells were co-transfected with 0.1 μg
of pEGFP-fAR and 0.4 μg of pGL3PSAp-5.8, and then cells were
further treated with adione, DHT and/or 2’HF for 24 hours. 
Apoptosis assay. To investigate whether 2’HF causes PCa cells to
undergo apoptosis, the Annexin-V-FLUOS Staining kit (Roche,
Mannheim, Germany) was used according to the manufacture’s
protocol. In brief, 1×105 LNCaP, and DU145 cells, and 5×104 PC-3
cells were seeded in 6-well plates with DMEM-5% CCS. They were
treated with 10 μM 2’HF for 72 hours. After removing the media
and washing by PBS, cells were incubated with 100 μl Annexin-V-
FLUOS labeling solution added with propidium iodide for 15 min at
room temperature. The stained cells were analyzed by fluorescence
microscope, FSX100 (Olympus, Tokyo, Japan).
Liquid chromatography mass spectometry/mass spectrometry (LC-
MS/MS). After plating 5×104 cells on 12-well plates in DMEM-5%
CCS, PC-3 cells were treated with 10 nM adione or 10 nM
testosterone in the absence and presence of 10 μM 2’HF. Then the
media were collected 24 hours later. The concentration of adione,
testosterone, and DHT in media was measured by LC-MS/MS
(Division of Pharmacological Research, Aska Pharma Medical Co.
Ltd., Kawasaki, Japan).
Visualization of AR localization. Twenty-four hours after
transfection of pEGFP-fAR into PC-3 cells, cells were treated with
or without 10 μM 2’HF for 24 hours. Consequently cells were
cultured in the absence or presence of 10 nM DHT for 8 hours, and
fAR fused to green fluorescent protein (GFP) was visualized by
FSX100.
Statistical analysis. Statistical significance was determined by using
Prism 6.0 software, the χ2 test was utilized to assess the significance
between different proportions. Analysis of continuous variables
between different groups was assessed by one-way analysis of
variance followed by Fisher’s protected least significant difference
test. *, **, and *** in Figure represent significant difference p<0.05,
p<0.01, and p<0.001, respectively. 
Results
Effect of 2’HF on PCa cell proliferation. In order to
investigate the effect on PCa cell proliferation, androgen-
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independent PC-3 and DU145 cells and androgen-sensitive
LNCaP cells were treated with 2’HF. As shown in Figure 1A,
the proliferation of PC-3 and DU145 cells was inhibited by
2’HF in a dose-dependent manner. In particular 10 μM 2’HF
inhibited the proliferation of PC-3 and DU145 cells to 22%
and 31% that of the controls, respectively. To determine
whether inhibition of proliferation of PC-3 and DU145 cells
by 2’HF was due to apoptosis, we performed annexin V
staining. PC-3 cells treated with 2’HF for 72 hours were
well-stained with Annexin-V-FLUOS, indicating apoptosis,
whereas PC-3 cells cultured in the absence of 2’HF were not
stained by green fluorescence. Similar results were observed
in DU145 cells (Figure 1B). 
As shown in Figure 1C, although 10 μM 2’HF also
inhibited the proliferation of LNCaP cells in the absence of
androgens to 59% that of the control, the inhibition of LNCaP
cells was less than that of PC-3 and DU145 cells. In contrast
to PC-3 and DU145 cells, the treatment of 10 μM 2’HF did
not influence staining by Annexin-V-FLUOS in LNCaP cells,
suggesting that apoptosis was not induced in LNCaP cells by
10 μM 2’HF (Figure 1D). However, 2’HF did inhibit the
stimulation of LNCaP cell proliferation by 10 nM adione in a
dose-dependent manner. This stimulation was almost
abolished to the basal level by 10 μM 2’HF. Of interest, the
proliferation of LNCaP cells stimulated by 1 nM testosterone
and 1 nM DHT was also inhibited by 2’-HF, suggesting that
2’HF inhibited the stimulation of cell proliferation by
testosterone and DHT without inhibiting testosterone synthesis
in LNCaP cells. We then investigated the effect of 2’HF on the
expression of PSA. LNCaP cells were treated with 10 nM
adione, or 1 nM DHT in the absence and presence of 2’HF.
As shown in Figure 1E, the induction of PSA mRNA
expression not only by adione but also by DHT was repressed
by 2’HF in a dose-dependent manner, although the basal level
of PSA mRNA was not changed by 2’HF. These results
suggest that 2’HF represses androgen-responsiveness in
LNCaP cells without affecting androgen synthesis.
2’HF represses androgen-induced PSA promoter activity in
PCa cells. In order to further investigate the effect of 2’HF
on AR activity, we transfected LNCaP cells with a luciferase
expression plasmid driven by the PSA promoter, pGL3PSAp-
5.8, which was induced by androgens, and performed
luciferase assay (4). As shown in Figure 2A, 10 μM 2’HF
did not repress the basal level of PSA promoter activity. In
contrast, 2’HF repressed PSA promoter activity induced by
10 nM adione, 1 nM testosterone and by 1 nM DHT in
LNCaP cells transfected with pGL3PSAp-5.8 in a dose-
dependent manner. Moreover, 10 μM 2’HF repressed these
inductions to the basal level of PSA promoter activity. Since
the AR gene in LNCaP cells is mutated at codon 877, this
mutation might affect this repression by 2’HF. To exclude
this possibility, we transfected PC-3 cells with a wild-type
AR expression plasmid vector (pSGAR2) and examined the
effect of 2’HF (Figure 2B). PSA promoter activity induced
by 10 nM adione and 1 nM testosterone in the presence of
wild-type AR was repressed by 10 μM 2’HF, suggesting that
2’HF might affect AR activity directly independently of
androgen concentration in the medium.
2’HF does not affect HSD17B and 5α-reductase activity in
PCa cells. Since 2’HF repressed AR activity induced by
testosterone and DHT, as well as adione, we determined if
2’HF affected the androgen concentration in medium from
cell cultures. We treated PC-3 cells with 10 nM adione or 10
nM testosterone in the absence and presence of 10 μM 2’HF
and measured the concentration of adione, testosterone, and
DHT in the medium 24 hours later by Liquid
chromatography mass spectometry/mass spectrometry (LC-
MS/MS). 2’HF did not change testosterone and DHT
concentration after addition of adione, and did not change
DHT concentration after the addition of testosterone,
suggesting that 2’HF does not affect HSD17B and 5α-
reductase activity in vitro (Figure 3). 
2’HF inhibited the expression of AR protein but not AR mRNA.
To reveal the mechanism of 2’HF repression AR activity, we
first investigated the expression level of AR mRNA in LNCaP
cells. Although 2’HF repressed the expression of PSA and
other androgen-responsive genes induced by adione,
testosterone, and DHT, the expression of AR mRNA did not
change regardless of the presence or absence of 2’HF (Figure
4A). Next we investigated whether 2’HF affects the expression
of AR protein. Western blot analysis revealed 2’HF down-
regulated the expression of AR protein in LNCaP cells in a
dose-dependent manner (Figure 4B). In addition, the level of
exogenous AR in PC-3 cells transfected with pSGAR2 driven
by SV40 promoter was also repressed by 2’HF. 
Nuclear localization of AR. AR is usually localized in the
cytoplasm in the absence of androgen and is translocated into
the nucleus in the presence of androgen. We determined
whether 2’HF affects AR localization. We transfected PC-3
cells with pEGFP-fAR plasmid that express full-length AR
fused to GFP protein and recorded AR localization in the
presence and absence of 2’HF. GFP-fAR protein, which was
localized in the cytoplasm in the absence of DHT, was
translocated into the nucleus in the presence of DHT within
8 hours (Figure 5). This translocation of AR into the nucleus
was blocked in the presence of 2’HF and AR was kept
staying in the cytoplasm even in the presence of DHT. 
Discussion
Once androgen-sensitive PCa becomes CRPC during first-
line hormonal therapy, physicians often conduct second-line
Ofude et al: Prostate Cancer and 2’-Hydroxyflavanone
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Figure 1. Effect of 2’HF on the proliferation of PC-3, DU145, and LNCaP cells. A: Twenty-four hours after 5×104 PC-3 or DU145 cells were plated,
cells were treated with the indicated concentrations of 2’HF, then cells were counted. The media were changed every two days. B: After 5×104 PC-3
or DU145 cells were plated onto 6-well plates, cells were treated for 72 hours with or without 10 μM 2’HF, they were incubated with 100 μl Annexin-
V-FLUOS labeling solution. They were analysed by phase contrast (left) and fluorescence microscopy (right). C: After LNCaP cells were treated with
0, 10 nM 4-androstenedione (adione) , 1 nM testosterone (T) , or 1 nM dihydrotestosterone (DHT) in the presence of the indicated concentration of 2’HF
for four days, the numbers of LNCaP cells were counted. D: LNCaP cells 1×105 were plated onto 6-well plates. Seventy-two hours after treatment with
or without 10 μM 2’HF, they were incubated with 100 μl Annexin-V-FLUOS labeling solution. They were analyzed by phase contrast (left) and
fluorescence (right) microscopy. E: Twenty-four hours after seeding of LNCaP cells, cells were treated with 10 nM Adione or 10 nM DHT in the presence
of indicated concentrations of 2’HF for 20 hours. The expression level of PSA mRNA was determined by RT-PCR. *p<0.05, ***p<0.001. 
hormonal therapy and sequentially conduct chemotherapy
using docetaxel. Although docetaxel is effective for 70% of
CRPC, CRPC eventually shifts to become docetaxel-
resistant. In such a situation, the prognosis of the patients is
poor. Therefore, it is extremely important to prevent PCa
from recurrence during hormonal therapy, without severe
side- effects.
Flavonoids have antitumor activity, inducing apoptosis via
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), nuclear transcription factor-κB (NF-κB) reactive
oxygen species, and peroxisome proliferator-activated
receptor-gamma (PPARγ)-dependent, and independent
pathways (21-24). Recently it was reported that among
flavanones, 2’HF showed the most potent tumor inhibitory
activity by stimulating caspase-mediated apoptosis of colon
cancer cells (25). This apoptosis by 2’HF was associated
with up-regulation of nonsteroidal anti-inflammatory drug-
activated gene 1 (NAG-1) expression through induction of
Ofude et al: Prostate Cancer and 2’-Hydroxyflavanone
4457
Figure 2. Effect of 2’HF on androgen receptor (AR) activity in prostate cancer cells. A: Twenty-four hours after transfection of LNCaP cells with
luciferase reporter plasmid (pGL3PSAp-5.8), cells were treated with 0, 10 nM 4-androstenedione (adione), 1 nM testosterone (T), or 1 nM
dihydrotestosterone (DHT) in the presence of the indicated concentrations of 2’HF for 24 hours, luciferase activity was then examined. B: Twenty-
four hours after transfection of PC-3 cells with 300 ng pGL3PSAp-5.8 and 200 ng pSGAR2, cells were treated with 0, 10 nM adione, or 1 nM T in
the absence or presence of 10 μM 2’HF for 24 hours, then luciferase activity was examined. 
Figure 3. Androgen biosynthesis from adione or testosterone in PC-3 cells. Twenty-four hours after starting culture of 5×104 PC-3 cells, 10 nM
adione or 10 nM testosterone was added to the medium. Aliquots of medium were collected after 24 hours for measuring the concentration of adione
, testosterone and testosterone (T).
EGR-1. 2’HF also inhibited cell cycle progression and
angiogenesis by reducing vascular endothelial growth factor
expression in von Hippel-Lindau (VHL)-mutant renal cell
carcinoma (26). In the present study, 2’HF inhibited
proliferation of androgen-independent PCa cells via
apoptosis at least. We are now investigating the mechanism
of apoptosis induced by 2’HF in PCa cells.
2’HF was also a candidate for repression of AKR1C3
activity that stimulates biosynthesis of testosterone from
adione (16). Contrary to our expectation, however, 2’HF did
not have an inhibitory effect on AKR1C3 activity in cultured
PCa cells. Instead, 2’HF repressed testosterone and DHT-
induced androgen responsiveness. In the present study, 2’HF
was shown, to our knowledge for the first time, to down-
regulate AR activity. This effect was mediated through down-
regulation of AR protein expression at least. We also
previously confirmed whether other candidates of dietary
flavonoids AKR1C3 inhibitors could affect AR activity. One
such candidate, naringenin, which is a strong AKR1C3
inhibitor, also repressed AR activity in the presence of DHT,
as well as adione (data not shown) (16). Naringenin may also
repress AR activity similarly to 2’HF without mediating
through AKR1C3. Moreover, 2’HF also inhibited AR
translocation into the nucleus. However, it is not clear
whether this inhibition is a result of inhibition of the nuclear
localization signal or of diminished AR expression. We accept
that 2’ HF may inhibit AKR1C3 activity and inhibit androgen
synthesis from adione to testosterone. A higher concentration
of 2’HF may inhibit AKR1C3 activity in PCa cells. 
Several mechanisms by which androgen-naïve PCa
changes to CRPC have been proposed, such as the existence
of hypersensitive AR, promiscuous AR, outlaw AR, bypass
AR, and alternative spliced truncated AR (27, 28). Existence
of adrenal androgen also affects the mechanisms by which
PCa becomes CRPC (29). Moreover, intratumoral androgen
synthesis, especially, in PCa-derived stromal cells and bone-
derived stromal cells, also play an important role in
activation of adrenal androgen (4, 30). Therefore, some
strategies to block the androgen AR axis have been
considered (31). These include: (i) Inhibition of androgen
synthesis enzyme upstream of DHEA synthesis in adrenal
gland, such as abiraterone acetate and TAK-700 (32, 33); (ii)
use of more potent antiandrogen agents, or inhibition of
nuclear translocation of AR, such as enzalutamide (34); (iii)
inhibition of androgen synthesis from DHEA in tumor cells
or stromal cells, e.g. using 5α-reductase inhibitors (35). (iv)
diminishing the AR level in PCa cells. Clinical evidence that
enzalutamide, abiraterone acetate, and TAK-700 are very
effective for CRPC even after docetaxel treatment have
proven that the androgen AR axis plays an extremely
important role in the transformation of PCa to CRPC (29,
36). However, strong inhibitors of androgen synthesis
enzymes such as HSD17B (AKR1C3) or HSD3B, in tumor
cells have not yet been identified. Moreover, it may be
difficult to overcome the progression of CRPC via the
androgen AR axis completely by inhibition of androgen
synthesis. Androgen-independent AR activation is also
indicated in the progression of CRPC via interleukin-6 (IL-
6) activation of signal transducer and activator of
transcription 3 (STAT3) (37, 38), and via IL-8 signaling
tyrosine kinases Src and focal adhesion kinase (FAK) (39,
40). If androgen-independent AR activation by cytokines
results in emergence of CRPC, the inhibition of androgen
synthesis would not be effective for these patients. In such
cases, repression of AR expression by 2’HF might be
effective for inhibition of the AR axis.
Recently, ASC-J9 was synthesized, which stimulates AR
degradation-repressed androgen responsiveness (41).
ANTICANCER RESEARCH 33: 4453-4461 (2013)
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Figure 4. Effect of 2’HF on PSA and AR mRNA and protein expression. A:
Twenty-four hours after seeding of LNCaP cells, cells were treated with or
without 10 nM adione, 10 nM testosterone (T) , or 10 nM
dihydrotestosterone (DHT) for 12 hours and harvested to extract total
RNA. The expression level of AR, PSA, and GAPDH mRNA was subjected
to RT-PCR. B: Twenty-four hours after seeding of LNCaP or PC-3 cells
transfected with pSGAR2 vector, cells were treated with indicated
concentration of 2’HF for 24 hours and then harvested. The expression
level of AR and GAPDH proteins were subjected to western blot analysis.
Curcumin which is a major natural yellow pigment in
turmeric and is widely used as a spice and coloring agent in
several foods such as curry, has also been shown to down-
regulate AR protein (42). We revealed that 2’HF similarly
represses AR activity by diminishing AR protein in PCa
cells. We will investigate whether 2’HF affects AR
ubiquitination and degradation of AR or affects AR
translation.
When advanced PCa changes to CRPC during hormonal
therapy, physicians often conduct docetaxel-based
chemotherapy, which can extend the survival period of the
patients (43). However, the effective period is limited
because of further progression of CRPC. Overcoming
docetaxel resistance, therefore, is important to improve the
prognosis of patients. One of mechanisms of taxane
resistance is up-regulation of P-glycoprotein expression (44).
Polymethoxyflavones, which are components of orange
juice, inhibit P-glycoprotein-mediated efflux (45). Since
flavonoids have a variety of functions for pharmacological
activity, 2’HF may also exhibit inhibitory activity on P-
glycoprotein and increase the sensitivity to docetaxel. As a
result, 2’HF might reduce adverse effects as well as
overcoming docetaxel resistance.
In conclusion, we revealed that the natural product, 2’HF,
found naturally in fruits and vegetables, can inhibit not only
the proliferation of PCa cells but also androgen
responsiveness via down-regulation of AR protein. If we can
prevent progression of PCa during ADT by taking natural
products such as 2’HF effectively, patients will be able to
benefit physiologically and economically. Further analyses
are needed to reveal the full range of pharmacological
activities of 2’HF.
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